Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan

Journal of Clinical Oncology

Volumn 19, Issue 14, 2001, Pages 3312-3322

  Gordon, A N ^a   Fleagle, J T ^a   Guthrie, D ^a   Parkin, D E ^a   Gore, M E ^a   Lacave, A J ^a  

^a TEXAS ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; PLATINUM; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; HUMAN; INFUSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0035879099     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.14.3312     Document Type: Article

References (47)

1. Cancer statistics, 2000
2. Advanced ovarian cancer: Recent progress and current challenges
3. Epithelial ovarian cancer
4. Treatment of advanced-stage ovarian cancer
5. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
6. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NO-COVA, NCIC CTG and Scottish intergroup trial
7. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
8. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study
9. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel
10. Phase II study of intravenous topotecan as a 5-day infusion for refractory ovarian carcinoma
11. A phase II trial of topotecan as a salvage therapy in epithelial ovarian cancer
12. Topotecan in platinum and paclitaxel-resistant ovarian cancer
13. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study
14. Treatment of refractory and recurrent ovarian cancer
15. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
16. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
17. Treatment of recurrent ovarian cancer: Increasing options - "Recurrent" results
18. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies
19. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
20. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
21. Stealth: Liposome technology - An overview
22. Transport of molecules across tumor vasculature
23. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules
24. Stealth liposomal doxorubicin (SLD): Delivers more doxorubicin (DOX) to AIDS-Kaposi's Sarcoma (AIDS-KS) lesions than to normal skin
25. Plasma pharmacokinetics of Adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols
26. Comparative pharmacokinetic study of Adriamycin and 4′epi-Adriamycin after their simultaneous intravenous administration
27. Biodistribution and pharmacokinetics of IN-111 labeled Stealth liposomes in patients with solid tumours
28. Pegylated liposomal doxorubicin: Scientific rationale and preclinical pharmacology
29. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international trials in oncology
30. Comparing treatments using quality-adjusted survival: The Q-TWiST method
31. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study
32. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer
33. Oral etoposide is active against platinum-resistant epithelial ovarian cancer
34. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients
35. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer
36. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease
37. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
38. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes
39. Effect of liposomes on P-glycoprotein function in multidrug resistant cells
40. Lower dose topotecan salvage chemotherapy remains active in platinum and paclitaxel-refractory and -resistant ovarian cancer
41. Pyridoxine for hand-foot syndrome
42. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
43. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
44. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, doubleblind clinical trial using a canine model
45. Initial clinical evaluation of pegylated-liposomal doxorubicin in solid tumors